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Summary
Background Polycystic ovary syndrome (PCOS) is one of the commonest endocrinopathy diagnosed among women 
mainly at reproductive age. For the first time it was described by Stein and Leventhal in 1935 and defined by two 
of the three findings: irregular menses (oligo-/amenorrhoea), hyperandrogenism or polycystic ovaries appearance 
on ultrasound, provided that other causes of androgen excess and dysovulation are excluded. PCOS is very often 
associated with infertility, endometrium cancer, obesity, insulin resistance, impaired glucose metabolism, higher risk 
for type 2 diabetes, high blood pressure, impaired lipid profile, mental illnesses and non-alcoholic liver steatosis. The 
presence of some of mentioned conditions may exacerbate the risk of cardiovascular events in women with PCOS [1, 2].
The main goal of our study was to assess the frequency of hypertension among women with PCOS. 
Material and methods Retrospective analysis of medical records of 213 women, age 17–42 (mean 25 ± 6 years).
Results Twenty-two women (10%) in examined group suffered from hypertension. The incidence of elevated blood 
pressure was higher among women with insulin resistance (p = 0.006). Prevalence odds ratio (OR) of arterial hyper-
tension in the group with hyperprolactinaemia was 0.15 (confidence interval [CI] 0.06–0.37) and in the group with 
insulin resistance (OR) 1.05 (CI 0.61–1.83). 
Conclusion The prevalence of hypertension among women with PCOS is higher when compared with healthy 
women at the same age. Thus, due to the young age of enrolled patients, it seems reasonable to recommend extension 
of the diagnostics of PCOS with blood pressure assessment.
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Background
Polycystic ovary syndrome (PCOS) is one of the 
commonest endocrinopathy diagnosed among wom-
en mainly at reproductive age. The prevalence of 
PCOS is dependent on diagnostic criteria, from 9% 
according to the NIH Consensus 1990, up to 18% 
with the Rotterdam consensus 2003 [1, 2]. For the 
first time it was described by Stein and Leventhal 
in 1935 and defined by two of the three findings: 
irregular menses (oligo-/amenorrhoea), hyperandro-
genism (clinical or/and biochemical examinations 
performed, if possible, in the follicular phase) or 
polycystic ovaries appearance on ultrasound (pres-
ence of more than 12 follicles of diameter 2–9 mm 
or ovarian volume greater than 10 cm3 [3], provided 
that other causes of androgen excess and dysovula-
tion are excluded. Irregularity of menses is defined 
as 8 or less cycles per year. Hirsutism is assessed 
according to Ferriman-Gallwey index. The presence 
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of hirsutism is more pronounced among Caucasian 
(around 70%), than in Asian (10%) women [1, 4]. 
According to the diagnostic criteria, PCOS may be 
divided into: “classic phenotype” PCOS character-
ised by hyperandrogenism and oligomenorrhoea 
with or without polycystic ovaries, “ovulatory phe-
notype” — hyperandrogenism and polycystic ovaries 
in normally ovulating women, “non-hyperandroge-
nic phenotype” — oligomenorrhoea and polycystic 
ovaries without overt hyperandrogenism [3]. Classic 
PCOS phenotype remains the most common variant 
of disease, with the prevalence of almost 70% [4].
PCOS is a complex endocrine disease, and due to 
uncertainty about its aetiology (it is probably deter-
mined by both environmental and genetic risk fac-
tors), heterogeneous clinical presentation and despite 
of the detailed diagnostic description may give lots 
of diagnostic and treatment disturbances. Besides 
of typical symptoms and signs, PCOS is very often 
associated with infertility, cancer of endometrium, 
obesity (prevalence ranging from 12.5 up to 100%), 
insulin resistance and compensatory hyperinsulinae-
mia (especially in the classic phenotype), impaired 
glucose metabolism, higher risk for type 2 diabetes 
(7.5–10%) [5], with 5- to 10-fold higher rate of pro-
gression from impaired glucose metabolism to overt 
type 2 diabetes [5], metabolic syndrome, high blood 
pressure, impaired lipid profile (higher levels of tri-
glycerides, LDL-cholesterol and total cholesterol and 
lower HDL cholesterol), mental illnesses (e.g. de-
pression), obstructive sleep apnoea and non-alcoho-
lic liver steatosis. The presence of the aforementioned 
conditions may increase risk of cardiovascular events, 
such as acute coronary syndrome (7-fold higher), 
coronary artery disease (1.5-fold higher), intrace-
rebral stroke (2.8-fold higher). However, the risk 
of increased cardiovascular morbidity and mortality 
has not yet been fully elucidated and needs further 
investigation [6]. 
Goal of the study 
The main goal of our study was to assess the fre-
quency of hypertension among women with PCOS 
as one of cardiovascular diseases and acute event risk 
factor. 
Material and methods
We performed a retrospective analysis of the med-
ical records of 213 women. We enrolled in the study 
patients between 17 and 42 (mean 25 ± 6 years) 
with established diagnosis of PCOS according to the 
Rotterdam Consensus Criteria. We divided the study 
population into a group with high blood pressure 
(with past medical history of artery hypertension or 
the blood pressure above 140/90 mmHg measured 
de novo) and a group with normal blood pressure. 
Blood pressure was measured twice a day, in the 
morning and before sleep or an ambulatory blood 
pressure monitoring (ABPM) was performed. Addi-
tionally, we assessed the correlation between insulin 
resistance, hyperprolactinaemia and artery hyperten-
sion. Data were statistically analysed using MS Office 
Excel and Statistica Software. 
Results
Twenty-two women (10% of examined group) 
suffered from hypertension. High blood pressure was 
found more frequently in the group with normal 
prolactin level (p < 0.001). Among women with 
insulin resistance blood pressure was higher than in 
the group with normal insulin sensitivity (p = 0.006). 
Prevalence odds ratio (OR) of arterial hypertension 
in the group of hyperprolactinaemia was 0.15 (con-
fidence interval [CI] 0.06–0.37) and in the group 
with insulin resistance odds ratio (OR) was 1.05 
(CI 0.61–1.83). Prevalence of high blood pressure, 
hyperprolactinaemia, insulin resistance, obesity, hy-
perlipidaemia, hyperandrogenism and hirsutism are 
shown in Table I. 
Discussion
Hypertension is one of the most common chronic 
diseases worldwide. According to the World Health 
Organisation, arterial hypertension is defined as sys-
tolic blood pressure (SBP) above 140 mmHg and 
diastolic blood pressure above 90 mmHg [6]. A ma-
jor problem associated with hypertension is its asym-
ptomatic nature, while serious risk factors of or-
gan damage might be found. Nowadays, high blood 
pressure affects around 1 billion people in the whole 
world and because of important links to the modern 
lifestyle it is considered as a disease of civilization 
of the XXI century [7]. Prognosis for 2015 predicts 
that cardiovascular diseases may cause 20 million 
deaths worldwide. The prevalence of hypertension 
varies depending on the geographical localization, 
socio-cultural and economic factors and usually it 
coexists with the level of industrialization as in the 
United States, Canada, Japan, Australia and most 
European countries. In Africa and the underdevel-
oped south of China the percentage of hypertension 
does not exceed 15% [8].
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Table I. Prevalence of high blood pressure, hyperprolactinemia, insulin 
resistance, obesity, hyperlipidemia, hyperandrogenism and hirsutism
Condition Number  
of patients
(%)
Artery hypertension 22 10
Hyperprolactinaemia 167 77
Insulin resistance 110 51
Obesity 74 34
Hyperandrogenism 82 37
Hyperlipidaemia 32 15
Hirsutism 41 19
The prevalence of hypertension in Western Eu-
rope and the US white population is moderate, 
around 15–30%, while in Poland, Russia, Finland 
and among African Americans in the United States 
is large and exceeds 30%. Epidemiologists say that 
between 2000 and 2025, the number of patients 
with hypertension can increase up to 60% [9, 10].
One of the Polish largest studies, NATPOL III 
PLUS (2002) among group of 3051 people, showed 
that the incidence of hypertension in Poland is 
around 29%. The frequency of high normal blood 
pressure rated at 30% [11–13]. There were not dif-
ferences between sex (women 29%, men 28.9%). 
The prevalence of hypertension in the young-
er group (18–39 years) was 7.2% (3.4% women 
vs. men 11%, p < 0.05) in the group of 40–59 years 
— 34.1% (34% women vs. men 34.1%), while 
in group over 59 years — 57.5% (59.9% women 
vs. men 54%) [14]. 
When comparing our results and younger group 
of women (18–39 years) from NATPOL III PLUS, 
we found that high blood pressure was more frequent 
among patients with PCOS (respectively 10% vs. 
3.4%). Additionally, higher blood pressure was also 
clearly marked in the group with PCOS and insulin 
resistance compared with the group with normal 
glucose metabolism.
Although the data on cardiovascular events in 
women in the reproductive age suffering from PCOS 
is scarce, the available literature suggests more fre-
quent cardiovascular diseases in classic PCOS phe-
notype [15]. Studies assessing an increased risk of 
morbidity and mortality due to cardiovascular diseases 
among these women are inconclusive [15]. Some of 
the PCOS’s studies revealed an association between 
high blood pressure and this endocrine condition. In 
the North East Brazil study the prevalence of artery 
hypertension was 2-fold higher in women with PCOS 
compared with non-PCOS group (p < 0.05) [6]. 
Chen and Young (2007) found that the free an-
drogen index ≥ 19% and low level of the sex hor-
mone binding globulin (SHBG) is associated with 
the increased risk of higher blood pressure [16]. In 
a China study [17] the prevalence of hypertension 
was only 1.2%, however, in a group of high blood 
pressure and PCOS they found higher level of glu-
cose, insulin, lipids and insulin resistance (calculated 
with HOMA index) and all of these differences were 
significant (p < 0.05) [17]. 
Study of the Tunisian National Institute of Nu-
trition showed that a family history of high blood 
pressure was not a risk factor for the same condition 
in PCOS women, but patients suffering both from 
PCOS and hypertension had a significantly higher 
level of triglyceride and BMI [18]. 
Holte et al. (1996) in a Swedish study revealed an 
association between higher day-time systolic blood 
pressure SBP (p < 0.05) and increased pulse rate 
(p < 0.05) among PCOS group but there were 
not differences in diastolic blood pressure DBP 
(p = 0.05) [19].
Higashi et al. (2002) found than in a group of 
PCOS women the nocturnal SBP did not fall by 
10% or more compared with day-time SBP, which 
is characteristic for “non-dipper” pattern of diurnal 
high blood pressure. This association is probably due 
to endothelial impairment and corroborates with 
insulin resistance and waist circumference [20]. 
Lifelong exposure to cardiovascular risk factors 
such as: metabolic syndrome, type 2 diabetes, obesi-
ty, dyslipidaemia, insulin resistance and hypertension 
may lead to premature atherosclerosis [6]. Accor-
ding to Women Ischaemia Evaluation Study (WISE), 
women with PCOS have a large number of CVD 
events [15]. Greater prevalence of coronary artery 
calcifications in PCOS group is independent of age 
and BMI [21]. Vascular calcifications cause arterial 
stiffness and endothelial dysfunction [22]. In some 
studies it was shown, that endothelial dysfunction was 
strongly associated with higher level of androgen and 
insulin resistance. Group of “classic phenotype” of 
PCOS is considered as worse cardiometabolic profile 
and higher risk of cardiovascular events compared 
with “non-hyperandrogenic phenotype” [22]. In ad-
dition, women with PCOS have more advanced cor-
onary artery disease (usually multivessel disease) [15]. 
Conclusion
The prevalence of hypertension among women 
with PCOS is higher than in general population at 
the same age. Thus, due to the young age of enrolled 
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patients (mainly women between 20 and 40 years of 
age), it seems reasonable to recommend extension of 
the diagnostic of PCOS with blood pressure assess-
ment, especially when PCOS is accompanied with 
obesity, insulin resistance, impaired glucose tolerance 
and lipid metabolism. Blood pressure should be rou-
tinely checked at each visit. Moreover, early diagno-
sis, proper treatment, prevention and monitoring of 
possible complications and organ damage caused by 
hypertension can contribute to a significant reduc-
tion of increased risk of cardiovascular disease. 
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